Explore the words cloud of the TACT project. It provides you a very rough idea of what is the project "TACT" about.
The following table provides information about the project.
UNIVERSITE DE STRASBOURG
|Coordinator Country||France [FR]|
|Total cost||3˙089˙569 €|
|EC max contribution||3˙089˙569 € (100%)|
1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
|Duration (year-month-day)||from 2020-04-01 to 2024-03-31|
Take a look of project's partnership.
|1||UNIVERSITE DE STRASBOURG||FR (STRASBOURG)||coordinator||549˙604.00|
|2||THE QUEEN'S UNIVERSITY OF BELFAST||UK (BELFAST)||participant||606˙345.00|
|3||ALMAC DISCOVERY LTD||UK (CRAIGAVON)||participant||303˙172.00|
|4||UNIVERSITY COLLEGE LONDON||UK (LONDON)||participant||303˙172.00|
|5||SPIROCHEM AG||CH (BASEL)||participant||281˙276.00|
|6||CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS||FR (PARIS)||participant||274˙802.00|
|7||WAGENINGEN UNIVERSITY||NL (WAGENINGEN)||participant||265˙619.00|
|8||HEIDELBERG PHARMA RESEARCH GMBH||DE (LADENBURG)||participant||252˙788.00|
|9||TECHNISCHE UNIVERSITAET MUENCHEN||DE (MUENCHEN)||participant||252˙788.00|
Antibody-Drug Conjugates (ADCs) are fast growing classes of oncology therapeutics. They consist in a highly potent cytotoxic drug connected via a linker to an antibody that is specifically targeting certain tumor markers. By combining the cytotoxicity of the drug and the targeting properties of the antibody, ADCs kill cancer cells whilst leaving the healthy cells unaffected, a marked improvement compared to classical chemotherapies. However, limitations still exist which could fuel the development of new generations of ADCs with improved therapeutical properties. Targeted Anti-Cancer Therapies (TACT) is an innovative, international, multidisciplinary training and research programme which thus aims to train 11 Early- Stage Researchers (ESRs) on the development of state-of-the-art anti-cancer therapeutics and equip them with transferable, future career-enhancing skills to create the next generation of experts in Europe. More specifically, TACT’s research programme will focus on key priorities for the conception of new and more potent generations of Protein-Drug Conjugates (PDCs): site-specific bioconjugation methods, more potent payloads, environment-specific cleavable linkers, more efficient protein-based targeting systems and new analytical tools for acute characterization. This will be achieved by exposing the ESRs to the leading intersectoral research scientists and laboratories in Europe who are active in this field. In doing so, TACT combines state-of-the-art research with excellent training in PDCs, one of the hot topics in cancer and targeted therapies.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TACT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "TACT" are provided by the European Opendata Portal: CORDIS opendata.
Synthetic biology of carbohydrate-binding proteins: engineering protein-carbohydrate interactions for diagnostics and cell targetingRead More
Creating Granular Materials Experts by Developing Experimental Calibrations for Computational MethodsRead More
Biosensing with ORGanic ElectronicSRead More